Updated Dec. 23, 2013 at 10:53 p.m.

Premium Lock Kidney disease drug developer Nephrogenex files for $46M IPO

Published: 2013-12-23 19:04:00
Updated: 2013-12-23 22:53:20

Nephrogenex's Pyridorin Nephrogenex's Pyridorin Image 1 of 2 · Next Image…

Nephrogenex's IPO proceeds will finance phase III clinical trials on its diabetic neuropathy drug candidate, a treatment that could compete against other compounds being developed by larger pharmas such as AbbVie, Pfizer and Eli Lilly. Read more about Nephrogenex's plans....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll